Template:Undifferentiated malignancy: Difference between revisions

From patholines.org
Jump to navigation Jump to search
Newer edit →
VisualWikitext
Mikael Häggström (talk | contribs)
Administrators, Editors, Image-reviewer, csmoderator, Interface administrators, Administrators, Upload Wizard campaign editors
7,148 edits
Templated
 
Mikael Häggström (talk | contribs)
Administrators, Editors, Image-reviewer, csmoderator, Interface administrators, Administrators, Upload Wizard campaign editors
7,148 edits
Line 4: Line 4:
Alternatively, a more comprehensive panel can be performed upfront, with the most pertinent panel suggested below (with main associated primary origins in parentheses), but it should be tailored to additional clues from each individual case:<ref>Partly inspired by:<br>{{cite journal| author=Beauchamp K, Moran B, O'Brien T, Brennan D, Crown J, Sheahan K | display-authors=etal| title=Carcinoma of unknown primary (CUP): an update for histopathologists. | journal=Cancer Metastasis Rev | year= 2023 | volume=  | issue=  | pages=  | pmid=37394540 | doi=10.1007/s10555-023-10101-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37394540  }} </ref>
Alternatively, a more comprehensive panel can be performed upfront, with the most pertinent panel suggested below (with main associated primary origins in parentheses), but it should be tailored to additional clues from each individual case:<ref>Partly inspired by:<br>{{cite journal| author=Beauchamp K, Moran B, O'Brien T, Brennan D, Crown J, Sheahan K | display-authors=etal| title=Carcinoma of unknown primary (CUP): an update for histopathologists. | journal=Cancer Metastasis Rev | year= 2023 | volume=  | issue=  | pages=  | pmid=37394540 | doi=10.1007/s10555-023-10101-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37394540  }} </ref>
*'''Mucicarmine''' (adenocarcinoma)
*'''Mucicarmine''' (adenocarcinoma)
:*'''CK7 and CK20''', see section below.
:*'''CK7 and CK20''' can give a broad indication of the primary site. Still use more specific immunohistochemistry stains instead or in addition where applicable. See table below for main patterns.
:*'''NKX3.1''' in males (prostate) or '''estrogen and progesterone receptor''' in females (reproductive tract).
:*'''NKX3.1''' in males (prostate) or '''estrogen and progesterone receptor''' in females (reproductive tract).
:*'''TTF-1''' (thyroid, lung)
:*'''TTF-1''' (thyroid, lung)
Line 13: Line 13:
*'''LCA (CD45)''' (hematopoietic)
*'''LCA (CD45)''' (hematopoietic)
*'''Synaptophysin''' (neuroendocrine)
*'''Synaptophysin''' (neuroendocrine)
;CK7 and CK20 in carcinomas of unknown primary site (CUPs)
'''CK7 and CK20''' can give a broad indication of the primary site. Still use more specific immunohistochemistry stains instead or in addition where applicable.
{| class="wikitable"
{| class="wikitable"
|+ Most common CK7 and CK20 patterns in carcinomas of unknown primary site (CUPs)<ref name="pmid29621151">{{cite journal| author=Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ilié M| title=Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site. | journal=Cancers (Basel) | year= 2018 | volume= 10 | issue= 4 | pages=  | pmid=29621151 | doi=10.3390/cancers10040108 | pmc=5923363 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29621151  }} </ref>
|+ Most common CK7 and CK20 patterns in carcinomas of unknown primary site (CUPs)<ref name="pmid29621151">{{cite journal| author=Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ilié M| title=Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site. | journal=Cancers (Basel) | year= 2018 | volume= 10 | issue= 4 | pages=  | pmid=29621151 | doi=10.3390/cancers10040108 | pmc=5923363 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29621151  }} </ref>

Revision as of 14:31, 7 November 2023

Undifferentiated malignancy

An initial panel of cytokeratin (CK, such as by CK AE1/AE3 cocktail), S100, vimentin and LCA (CD45) can be used (see source article for subsequent work-up).[1]

Alternatively, a more comprehensive panel can be performed upfront, with the most pertinent panel suggested below (with main associated primary origins in parentheses), but it should be tailored to additional clues from each individual case:[2]

  • Mucicarmine (adenocarcinoma)
  • CK7 and CK20 can give a broad indication of the primary site. Still use more specific immunohistochemistry stains instead or in addition where applicable. See table below for main patterns.
  • NKX3.1 in males (prostate) or estrogen and progesterone receptor in females (reproductive tract).
  • TTF-1 (thyroid, lung)
  • GATA3 (urothelial)
  • CDX2 (gastrointestinal)
  • p63 (squamous cell carcinoma)
  • S100 (neural, melanoma)
  • LCA (CD45) (hematopoietic)
  • Synaptophysin (neuroendocrine)
Most common CK7 and CK20 patterns in carcinomas of unknown primary site (CUPs)[3]
CK20
Positive Negative
CK7 Positive
  • Urothelial carcinoma
  • Pancreatic adenocarcinoma
  • Ovarian mucinous carcinoma
  • Bladder adenocarcinoma
  • Gastric adenocarcinoma
  • Cholangiocarcinoma
  • Breast carcinoma
  • Lung adenocarcinoma
  • Endometrial adenocarcinoma
  • Endocervical adenocarcinoma
  • Ovarian (serous) carcinoma
  • Cholangiocarcinoma
  • Small cell lung carcinoma
  • Mesothelioma
  • Thyroid carcinoma
  • Salivary gland tumours
  • Kidney (papillary)
  • Urothelial carcinoma (subset)
  • Pancreatic adenocarcinoma
  • Gastric adenocarcinoma
  • Esophageal adenocarcinoma[4]
Negative
  • Colorectal adenocarcinoma
  • Merkel cell carcinoma
  • Gastric adenocarcinoma
  • Prostate adenocarcinoma
  • Renal (clear cells)
  • Hepatocellular carcinoma
  • Adrenocortical carcinoma
  • Non-seminoma germ cell tumours
  • Mesothelioma
  • Small cell lung carcinoma
  • Gastric adenocarcinoma

Notes


Main page

References

  1. ↑ Lin F, Liu H (2014). "Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin. ". Arch Pathol Lab Med 138 (12): 1583-610. doi:10.5858/arpa.2014-0061-RA. PMID 25427040. Archived from the original. . 
  2. ↑ Partly inspired by:
    Beauchamp K, Moran B, O'Brien T, Brennan D, Crown J, Sheahan K (2023). "Carcinoma of unknown primary (CUP): an update for histopathologists. ". Cancer Metastasis Rev. doi:10.1007/s10555-023-10101-6. PMID 37394540. Archived from the original. . 
  3. ↑ Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ilié M (2018). "Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site. ". Cancers (Basel) 10 (4). doi:10.3390/cancers10040108. PMID 29621151. PMC: 5923363. Archived from the original. . 
  4. ↑ Elliot Weisenberg, M.D.. Esophagus - Carcinoma - Adenocarcinoma. Pathology Outlines. Last author update: 1 June 2013. Last staff update: 31 October 2022

Image sources


Retrieved from "https://patholines.org/index.php?title=Template:Undifferentiated_malignancy&oldid=6905"